Search

Your search keyword '"Díaz-Manera, Jordi"' showing total 543 results

Search Constraints

Start Over You searched for: Author "Díaz-Manera, Jordi" Remove constraint Author: "Díaz-Manera, Jordi"
543 results on '"Díaz-Manera, Jordi"'

Search Results

1. Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.

2. Clinical and imaging spectrum of non-congenital dominant ACTN2 myopathy

4. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).

5. Imaging mass cytometry analysis of Becker muscular dystrophy muscle samples reveals different stages of muscle degeneration

9. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.

10. Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP-mediated disease reveals characteristic features useful for diagnosis

11. Disease-associated comorbidities, medication records and anthropometric measures in adults with Duchenne muscular dystrophy

12. Correction to: Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP‑mediated disease reveals characteristic features useful for diagnosis

13. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial

15. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry

16. Muscle magnetic resonance imaging of a large cohort of distal hereditary motor neuropathies reveals characteristic features useful for diagnosis

17. Expanding the muscle imaging spectrum in dysferlinopathy: description of an outlier population from the classical MRI pattern

19. Myostatin and follistatin as monitoring and prognostic biomarkers in dysferlinopathy

21. Muscle MRI characteristic pattern for late-onset TK2 deficiency diagnosis

23. Systematic Collaborative Reanalysis of Genomic Data Improves Diagnostic Yield in Neurologic Rare Diseases

24. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

25. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

27. Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease

29. Improving outcome measures in late onset Pompe disease: Modified Rasch‐Built Pompe‐Specific Activity scale.

31. Genotype–phenotype correlations in recessive titinopathies

32. Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness

33. Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy

34. Corrigendum to “Home infusion experience in patients with Pompe disease receiving avalglucosidase alfa during three clinical trials” [Molecular Genetics and Metabolism, 143 (2024) 108608]

39. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease:a phase III open-label extension study (ATB200-07)

40. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

41. MYO-MRI diagnostic protocols in genetic myopathies

42. Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT

43. Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy

44. Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids

46. Single cell RNA sequencing of human FAPs reveals different functional stages in Duchenne muscular dystrophy.

47. Association of Initial Maximal Motor Ability with Long-term Functional Outcome in Patients with COL6-related Dystrophies

48. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry

49. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

Catalog

Books, media, physical & digital resources